ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2855

Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program

Iain McInnes1, Matthias Kormaksson 2, Effie Pournara 3, Gregory Ligozio 2, Luminita Pricop 4, Peter Nash 5, Bruce Kirkham 6, Kristian Reich 7 and Christopher Ritchlin 8, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Novartis Pharmaceutical Corporation, New Jersey, NJ, 3Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5University of Queensland, Brisbane, Queensland, Australia, 6Guy's & St Thomas' NHS Foundation Trust, London, England, United Kingdom, 7University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, 8Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T116: Spondyloarthritis Including Psoriatic Arthritis – Clinical VI: Psoriatic Arthritis Clinical Studies (2852–2857)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Identifying clinically relevant patient phenotypes amidst the variability and heterogeneity of the clinical manifestations of psoriatic arthritis (PsA) is currently challenging.  Using machine-learning (ML) techniques could be the first critical step towards better understanding of disease pathotypes, and support progression towards precision medicine.1 Clusters of PsA patients based on presence/absence of disease domains were identified using ML from the secukinumab FUTURE trials program.

Methods: Hierarchical clustering was performed on the composite using “1-correlation” as the dissimilarity metric and Ward’s agglomeration method for pairwise grouping; a dendrogram was used to visualize and assess the resulting groupings. Pairwise correlations were explored in various clinical domains of PsA including dactylitis, NAPSI, PASI, enthesitis, swollen or tender joints, spondylitis, and CRP measurements from >2,700 patients across five phase 3 studies with ≈425,000 data entries at baseline and were visualized using heatmaps. Mixture (of Bernoullis) Model was applied to obtain the clusters across all domains. The model assumes that two patients share a cluster only if they have similar probability of presence of symptom across all clinical domains.

Results: The hierarchical clustering algorithm grouped the 78 individual joints into distinct and natural clusters. At higher level of the dendrogram, the algorithm grouped separately all foot, larger (jaws, clavicles, ankles, hips, wrists, knees, shoulders, elbows), and hand joints. An example for hierarchical clustering of 78 joints is shown in Figure 1. Cutting the dendrogram at 15 clusters separated all the joints into distinct groups; hand joints (distal and proximal phalanges, metacarpals and thumbs), and foot joints (distal and proximal phalanges, metatarsals and big toes). Associations of the joint clusters with other disease manifestations such as skin and nail involvement revealed distinct patient clusters, enabling to investigate differences in disease pathogenesis and treatment outcomes. For example, in one of the clusters with patients having high polyarticular burden (high number of affected joints), there was a high probability of nail involvement and psoriasis. These clusters were further refined when response to treatment over time was added in the model.

Conclusion: Machine learning methodology confirmed a natural grouping of joints in patients with psoriatic arthritis based on baseline swelling and tenderness and revealed complex correlation patterns. Additional cluster analyses including psoriatic arthritis disease manifestations and response to treatment revealed distinct patient clusters with potential clinical implications.

Reference: 

  1. Grys BT et al., J Cell Biol. 2017; 216(1): 65-71.

Figure 1. Dendrogram of Hierarchical Clustering of 78 Joints


Disclosure: I. McInnes, Abbott, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche., 2, 8, Abbvie, 5, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Astra Zeneca, 2, 5, AstraZeneca, 5, BI, 2, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Janssen, 2, 5, 8, Leo, 5, Lilly, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8; M. Kormaksson, Novartis, 3; E. Pournara, Novartis, 3; G. Ligozio, Novartis, 1, 3; L. Pricop, Noavrtis, 1, 3, Novartis, 1, 3, 4; P. Nash, AbbVie, 2, 5, 8, Abbvie, 2, 8, Amgen, 2, 5, 8, BMS, 2, 5, 8, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 8, Lilly, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8; B. Kirkham, AbbVie, 2, 5, 8, Gilead, 2, 5, 8, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Novartis, 2, 5, 8; K. Reich, AbbVie, 5, 8, Abbvie, 5, 8, Affibody, 5, 8, Almirall, 5, 8, Amgen, 5, 8, Biogen, 5, 8, Biogen-Idec, 5, 8, Boehringer Ingelheim, 5, 8, Boehringer Ingelheim Pharma, 5, 8, Celgene, 5, 8, Centocor, 5, 8, Covagen, 5, 8, Forward Pharma, 5, 8, GlaxoSmithKline, 5, 8, Janssen-Cilag, 5, 8, Janssen-Cliag, 5, 8, Kyowa Kirin, 5, 8, Leo, 5, 8, Lilly, 5, 8, Medac, 5, 8, Merck Sharp & Dohme, 5, 8, Miltenyi, 5, 8, Mltenyi, 5, 8, Novartis, 5, 8, Novatris, 5, 8, Ocean Pharma, 5, 8, Pfizer, 5, 8, Samsung Bioepis, 5, 8, Sanofi, 5, 8, Takeda, 5, 8, UCB, 5, 8, Valeant, 5, 8, Xenoport, 5, 8; C. Ritchlin, AbbVie, 2, 5, 9, Amgen, 2, 5, BMS, 5, Janssen, 5, Janssen Research & Development, LLC, 2, Lilly, 5, Novartis, 5, Pfizer, 2, Pfizer Inc, 5, UCB, 2, 5.

To cite this abstract in AMA style:

McInnes I, Kormaksson M, Pournara E, Ligozio G, Pricop L, Nash P, Kirkham B, Reich K, Ritchlin C. Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinically-relevant-patient-clusters-identified-by-machine-learning-tools-in-a-large-database-from-the-secukinumab-psoriatic-arthritis-clinical-development-program/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinically-relevant-patient-clusters-identified-by-machine-learning-tools-in-a-large-database-from-the-secukinumab-psoriatic-arthritis-clinical-development-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology